Cover Image
市場調查報告書

神經膠質肉瘤:開發中產品分析

Gliosarcoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245977
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
Back to Top
神經膠質肉瘤:開發中產品分析 Gliosarcoma - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 187 Pages
簡介

神經膠質肉瘤是發生在神經膠細胞的一種腦瘤。這種腦瘤會急速成長,跟據不同部位大小症狀有頭痛、嘔心、認知障礙、昏睡等。治療方法依腫種種類、階段、大小、發生部位、患者年齡及健康狀態而定。

本報告提供神經膠質肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

神經膠質肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amgen Inc.
  • Burzynski Research Institute, Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Sanofi

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • alisertib
  • Antineoplaston Therapy
  • CC-122
  • DNX-2401
  • indoximod
  • lonafarnib
  • Oncolytic Virus to Target IL-12 for Oncology
  • plerixafor
  • rilotumumab
  • SGT-53
  • Stem Cell Therapy for Glioma

開發中產品的最新趨勢

暫停的計劃

開發計劃的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9388IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Gliosarcoma - Overview 6
  • Gliosarcoma - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 10
  • Products under Development by Companies 11
  • Products under Development by Universities/Institutes 13
  • Gliosarcoma - Therapeutics Assessment 14
  • Assessment by Target 14
  • Assessment by Mechanism of Action 17
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Gliosarcoma - Companies Involved in Therapeutics Development 24
  • Agenus Inc 24
  • Bristol-Myers Squibb Company 24
  • Celgene Corp 25
  • DelMar Pharmaceuticals Inc 25
  • ERC Belgium SA 26
  • Merck & Co Inc 26
  • Merrimack Pharmaceuticals Inc 27
  • Millennium Pharmaceuticals Inc 27
  • NewLink Genetics Corp 28
  • Northwest Biotherapeutics Inc 28
  • Novartis AG 29
  • Nuo Therapeutics Inc 29
  • Progenics Pharmaceuticals Inc 29
  • Tragara Pharmaceuticals Inc 30
  • Gliosarcoma - Drug Profiles 31
  • ALD-451 - Drug Profile 31
  • alisertib - Drug Profile 32
  • avadomide hydrochloride - Drug Profile 38
  • BMS-986016 - Drug Profile 40
  • dasatinib - Drug Profile 42
  • DCVax-L - Drug Profile 45
  • dianhydrogalactitol - Drug Profile 53
  • DNX-2401 - Drug Profile 68
  • ERC-1671 - Drug Profile 72
  • flucytosine + TBio-01 - Drug Profile 73
  • G-200 - Drug Profile 74
  • indoximod - Drug Profile 77
  • irinotecan hydrochloride - Drug Profile 83
  • irinotecan hydrochloride + TBio-02 - Drug Profile 95
  • lonafarnib - Drug Profile 97
  • M-032 - Drug Profile 99
  • marizomib - Drug Profile 100
  • p28 - Drug Profile 105
  • pazopanib hydrochloride - Drug Profile 107
  • pembrolizumab - Drug Profile 115
  • PSMA ADC - Drug Profile 167
  • RRX-001 - Drug Profile 171
  • sapanisertib - Drug Profile 173
  • SGT-53 - Drug Profile 176
  • TG-02 - Drug Profile 178
  • urelumab - Drug Profile 181
  • Gliosarcoma - Dormant Projects 184
  • Appendix 185
  • Methodology 185
  • Coverage 185
  • Secondary Research 185
  • Primary Research 185
  • Expert Panel Validation 185
  • Contact Us 185
  • Disclaimer 186

List of Tables

  • Number of Products under Development for Gliosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Gliosarcoma - Pipeline by Agenus Inc, H1 2017
  • Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Gliosarcoma - Pipeline by Celgene Corp, H1 2017
  • Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
  • Gliosarcoma - Pipeline by ERC Belgium SA, H1 2017
  • Gliosarcoma - Pipeline by Merck & Co Inc, H1 2017
  • Gliosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Gliosarcoma - Pipeline by NewLink Genetics Corp, H1 2017
  • Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Gliosarcoma - Pipeline by Novartis AG, H1 2017
  • Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H1 2017
  • Gliosarcoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Gliosarcoma - Pipeline by Tragara Pharmaceuticals Inc, H1 2017
  • Gliosarcoma - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Gliosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top